# Coronavirus Situation Report

#### Sannidhi Sarvadhavabhatla

## 7/22/2020

### **Definition of COVID-19**

COVID-19 is officially named as "severe acute respiratory syndrome coronavirus 2" (also known as SARS-CoV-2)<sup>7</sup>. Those who are older or have any underlying medical conditions may be at a higher risk for contracting the virus.

##Situation by Numbers<sup>1</sup>

Table 1: Situation by numbers as July 11, 2020


Geographic_Regions	Total_Cases	Total_Deaths
Globally	7941791	434796
Africas	181903	4235
Americas	3841609	203574
Eastern Mediterranean	796759	17558
Europe	2434184	188779
South East Asia	486673	13409
Western Pacific	199922	7228

#### Risk Assessment

Currently, the Global Risk Assessment is Very High.


## Surveillence

## Map




### Graph

## Total Confirmed Cases as of July 11, 2020



## Total Deaths as of July 11, 2020



 $Table^{11}$ 

Reporting_Area	Total_Confirmed	Total_Deaths	Transmission_Classification
South Africa	350879	4948	Community transmission
Nigeria	36107	778	Community transmission
Ghana	27060	145	Community transmission
Algeria	22549	1068	Community transmission
Cameroon	16157	373	Community transmission
Kenya	12750	225	Community transmission
Ethiopia	9503	167	Community transmission
Senegal	8669	163	Community transmission
Democratic Republic of the Congo	8249	192	Community transmission
Madagascar	6849	55	Community transmission
Guinea	6491	39	Community transmission
Gabon	6121	46	Community transmission
Mauritania	5710	151	Community transmission
Central African Republic	4485	55	Community transmission
Zambia	2980	120	Community transmission
Malawi	2907	59	Clusters of cases
Congo	2633	49	Community transmission
Mali	2472	121	Community transmission
Equatorial Guinea	2350	41	Community transmission
South Sudan	2200	43	Community transmission
Cabo Verde	2014	21	Clusters of cases
Guinea-Bissau	1950	26	Community transmission
Eswatini	1729	21	Community transmission  Community transmission
Sierra Leone	1729	65	Community transmission  Community transmission
Benin	1602	31	· ·
Rwanda	1539	51 5	Community transmission
	1478	$\frac{5}{25}$	Community transmission Clusters of cases
Zimbabwe	1478	10	
Mozambique Namibia	1203	2	Community transmission Clusters of cases
Niger	1104	69	Community transmission
Liberia	1088	70	Community transmission
Uganda	1062	0	Clusters of cases
Burkina Faso	1047	53	Community transmission
Chad	889	75	Community transmission
Togo	774	15	Community transmission
Sao Tome and Principe	743	14	Clusters of cases
Angola	687	29	Clusters of cases
Botswana	522	1	Clusters of cases
United Republic of Tanzania	509	21	Community transmission
Lesotho	359	6	Clusters of cases
Mauritius	343	10	Sporadic cases
Comoros	328	7	Community transmission
Burundi	310	1	Clusters of cases
Eritrea	251	0	Sporadic cases
Seychelles	108	0	Sporadic cases
Gambia	93	4	Sporadic cases
Mayotte	2782	37	Clusters of cases
Réunion	624	3	Clusters of cases
United States of America	3544143	137674	Community transmission
Brazil	2046328	77851	Community transmission

Reporting_Area	Total	_Confirmed	Total_	Deaths	Transmission_Classification
Peru		345537		12799	Community transmission
Mexico		331298		38310	Community transmission
Chile		328846		8445	Community transmission
Colombia		182140		6288	Community transmission
Argentina		119301		2204	Community transmission
Canada		109669		8839	Community transmission
Ecuador		73382		5282	Community transmission
Bolivia (Plurinational State of)		56102		2049	Community transmission
Dominican Republic		51519		971	Community transmission
Panama		51408		1038	Community transmission
Guatemala		33809		1443	Community transmission
Honduras		31745		857	Community transmission
El Salvador		11508		324	Community transmission
Venezuela (Bolivarian Republic of)		11191		107	Community transmission
Costa Rica		9969		47	Community transmission
Haiti		6975		146	Community transmission
Paraguay		3457		28	Community transmission
Nicaragua		2712		99	Community transmission
Cuba		2445		87	Clusters of cases
Uruguay		1037		32	Clusters of cases
Suriname		943		19	Clusters of cases
Jamaica		768		10	Clusters of cases
Guyana		320		19	Clusters of cases
Trinidad and Tobago		136		8	Sporadic cases
Bahamas		129		11	Clusters of cases
Barbados		104		7	Clusters of cases
Antigua and Barbuda		76		3	Clusters of cases
Belize		40		$\overset{\circ}{2}$	Sporadic cases
Saint Vincent and the Grenadines		35		0	Sporadic cases
Grenada		23		0	Clusters of cases
Saint Lucia		23		0	Sporadic cases
Dominica		18		0	Clusters of cases
Saint Kitts and Nevis		17		0	No cases
Puerto Rico		11453		178	Community transmission
French Guiana		6655		37	Community transmission
United States Virgin Islands		283		6	Clusters of cases
Martinique		262		15	Clusters of cases
Cayman Islands		203		1	Clusters of cases
Guadeloupe		195		14	Clusters of cases
Bermuda		152		9	Sporadic cases
Aruba		108		3	Sporadic cases
Sint Maarten		79		15	No cases
Turks and Caicos Islands		75		$\overset{-3}{2}$	Clusters of cases
Saint Martin		46		3	Sporadic cases
Curação		28		1	No cases
Falkland Islands (Malvinas)		13		0	No cases
Montserrat		12		1	No cases
Bonaire, Sint Eustatius and Saba		10		0	No cases
British Virgin Islands		8		1	No cases
Saint Pierre and Miquelon		4		0	Sporadic cases
Anguilla		3		0	No cases
Iran (Islamic Republic of)		271606		13979	Community transmission
· · · · /					v

Reporting_Area	Total_	_Confirmed	Total_	_Deaths	Transmission_Classification
Pakistan		263496		5568	Clusters of cases
Saudi Arabia		248416		2447	Clusters of cases
Qatar		106308		154	Community transmission
Iraq		90220		3691	Community transmission
Egypt		87172		4251	Clusters of cases
Oman		65504		308	Community transmission
Kuwait		58904		407	Clusters of cases
United Arab Emirates		56711		338	Community transmission
Bahrain		36004		124	Clusters of cases
Afghanistan		35475		1181	Clusters of cases
Morocco		17015		269	Clusters of cases
Sudan		10762		680	Community transmission
Djibouti		5003		56	Clusters of cases
Somalia		3111		93	Sporadic cases
Lebanon		2775		40	Clusters of cases
Libya		1791		48	Clusters of cases
Yemen		1585		444	Community transmission
Tunisia		1348		50	Sporadic cases
Jordan		1214		11	Clusters of cases
Syrian Arab Republic		496		25	Community transmission
occupied Palestinian territory		9587		62	Clusters of cases
Russian Federation		771546		12342	Clusters of cases
The United Kingdom		294070		45273	Community transmission
Spain		260255		28420	Clusters of cases
Italy		244216		35042	Community transmission
Turkey		218717		5475	Community transmission
Germany		201574		9084	Clusters of cases
France		164247		30046	Clusters of cases
Sweden		77281		5619	Community transmission
Kazakhstan		70339		375	Clusters of cases
Belarus		65953		495	Community transmission
Belgium		63706		9800	Community transmission
Ukraine		58842		1485	Community transmission
Netherlands		51526		6129	Community transmission
Portugal		48390		1684	Community transmission
Israel		48041		395	Pending
Poland		39746		1618	Community transmission
Romania		36691		2009	Community transmission
Armenia		34877		641	Community transmission
Switzerland		33406		1687	Community transmission
Azerbaijan		27133		349	Clusters of cases
Ireland		25750		1753	Clusters of cases
Kyrgyzstan		24984		923	Clusters of cases
Republic of Moldova		20794		680	Community transmission
Serbia		20498		461	Community transmission
Austria		19508		711	Community transmission
Uzbekistan		16429		84	Clusters of cases
Czechia		13855		358	Clusters of cases
Denmark		13173		611	Community transmission
North Macedonia		9026		414	Clusters of cases
Norway		9015		255	Clusters of cases
Bulgaria		8638		299	Clusters of cases

Reporting_Area	Total_Confirmed	Total_Deaths	Transmission_Classification
Bosnia and Herzegovina	8164	245	Community transmission
Finland	7318	328	Clusters of cases
Tajikistan	6834	57	Pending
Luxembourg	5409	111	Community transmission
Hungary	4315	596	Community transmission
Croatia	4235	120	Clusters of cases
Albania	4008	111	Clusters of cases
Greece	3983	194	Clusters of cases
Estonia	2021	69	Clusters of cases
Slovakia	1976	28	Clusters of cases
Slovenia	1940	111	Clusters of cases
Iceland	1922	10	Community transmission
Lithuania	1915	80	Community transmission
Montenegro	1664	30	Clusters of cases
Latvia	1189	31	Clusters of cases
Cyprus	1037	19	Clusters of cases
Georgia	1028	15	Sporadic cases
Andorra	880	52	Community transmission
San Marino	716	$\frac{32}{42}$	Community transmission
Malta	674	9	Sporadic cases
Monaco	99	1	Sporadic cases
Liechtenstein	86	1	Sporadic cases
Holy See	12	0	Sporadic cases
Kosovo	5574	120	Community transmission
Isle of Man	336	$\frac{120}{24}$	No cases
	331	31	
Jersey	$\begin{array}{c} 551 \\ 252 \end{array}$	13	Community transmission
Guernsey			Community transmission
Faroe Islands	188	0	Pending
Gibraltar	180	0	Clusters of cases
Greenland	13	0	No cases
India	1077618	26816	Clusters of cases
Bangladesh	202066	2581	Community transmission
Indonesia	84882	4016	Community transmission
Nepal	17502	40	Clusters of cases
Thailand	3249	58	Clusters of cases
Maldives	2930	15	Clusters of cases
Sri Lanka	2708	11	Clusters of cases
Myanmar	341	6	Clusters of cases
Bhutan	87	0	Sporadic cases
Timor-Leste	24	0	No cases
China	85937	4653	Clusters of cases
Philippines	65304	1773	Community transmission
Singapore	47656	27	Clusters of cases
Japan	24642	985	Clusters of cases
Republic of Korea	13745	295	Clusters of cases
Australia	11441	118	Clusters of cases
Malaysia	8764	122	Clusters of cases
New Zealand	1203	22	Clusters of cases
Viet Nam	382	0	Clusters of cases
Mongolia	287	0	Sporadic cases
Cambodia	171	0	Sporadic cases
Brunei Darussalam	141	$\stackrel{\circ}{3}$	No cases
dio or abbailanti	141	9	2.0 00000

Reporting_Area	Total_Confirmed	Total_Deaths	Transmission_Classification
Fiji	26	0	Sporadic cases
Lao People's Democratic Republic	19	0	Sporadic cases
Papua New Guinea	15	0	Sporadic cases
Guam	307	5	Clusters of cases
French Polynesia	62	0	Sporadic cases
(Commonwealth of the)	37	2	Pending
New Caledonia	22	0	Sporadic cases

#### Transmission Classification:

- Community transmission: people within a certain area have been infected with the virus, some don't know who or where they became infected
- Cluster of cases: an aggregate of cases that are grouped in a specific place and time that is appeared to be greater than expected
- Sporadic cases: infrequent or irregular appearance of cases
- No Cases: no known individuals have been infected with the virus

#### **Incidence Rate:**

- Low: There have been 10 or fewer new cases per 100,000 people in the past two weeks
- Moderate: There have been between 10 and 50 new cases per 100,000 people in the past two weeks.
- Moderately High: There have been between 50 and 100 new cases per 100,000 people in the past two weeks.
- High: There have been more than 100 new cases per 100,000 people in the past two weeks.

#### Guidelines by CDC

#### Recommendations

The CDC recommends that all individuals should wear a mask when in public and practice social distancing of at least 6 feet. Gatherings should be limited to <10 people. Social distancing, also known as "physical distancing" is important as the droplets from one individual's sneeze, cough can be spread and land onto another person's nose or mouth and get into the lungs.

Additionally, people who are infected with the virus, but don't show any symptoms (asymptomatic) also can spread the virus.

It is also possible to get infected by touching a surface that may have been exposed to the virus and then touching your face, nose, mouth. However, this isn't the most common cause of the spread of the virus, as the virus can't survive long hours on surfaces.

### **Current Treatments**

Currently, there is no vaccine for the SARS-CoV-2. However, there are various treatments that are being tested in hospitals.

People with mild symptoms are able to recover at home with over the counter medication (pain killers, decongestants, cough suppressants).

The FDA and CDC both disagree on the effect of hydroxychloroquine, the malaria drug, to prevent COVID-19. A UK study said that "in a group of 1542 hospitalized patients treated with hydroxychloroquine, 25.7% had died after 28 days, compared with 23.5% in a group of 3132 patients who had only received standard care" This rules out the benefit of this drug.

The drug remdesivir, is a new intravenous antiviral that hasn't been approve yet but is far along on their clinical trial phase. This drug has been shown to have some effect against SARS, MERS, and Ebola. Ourrent studies, in vitro, have shown that remdesivir prevented human cells from being infected with the coronavirus. Currently, the FDA approved this drug for EUA, emergency use authorization on May 1, 2020.

Another drug, dexamethasone, is a common steroid used to treat many autoimmune conditions and allergic reactions. <sup>10</sup> A UK study seemed to suggest that this drug is helpful for patients who were on a ventilator or needed more oxygen due to the virus.

Lastly, an antibiotic azithromycin, is commonly used to treat bacterial infections such as bronchitis and pneumonia.<sup>10</sup> It was shown that this antibiotic had "some in vitro activity against viruses like influenza A and Zika, but did not work against the coronavirus that causes MER."<sup>10</sup>

Update July 20, 2020

AstraZeneca<sup>4</sup> published their study of a phase 1/2, single-blind, randomized controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. 1077 healthy adults aged 18–55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned to receive ChAdOx1 nCoV-19. There were no serious adverse events related to ChAdOx1 nCoV-19. ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody. One dose was sufficient to elicit some antibody response in over 90% of people, and a second dose pushed it to 100%, at levels similar to what's observed in convalescent patients.<sup>4</sup>

#### Testing

"The number of people infected with the coronavirus in different parts of the United States was anywhere from two to 13 times higher than the reported rates for those regions." CDC is working with a commercial laboratory and conducted a survey that tested blood specimens from people in Connecticut, Louisiana, Minnesota, Missouri, New York City, Philadelphia, San Francisco, South Florida, Utah and Western Washington State for SARS-CoV-2 antibodies. The results from the blood samples suggest that people who don't seek medical care or are asymptomatic to the virus are being unreported in the public data.

#### **Test Diagnostics**

I will be analyzing the effectiveness of the Roche COVID-19 Serology Antibody Test through sensitivity and specificity. Sensitivity is the probability of test being positive if one has the disease, while specificity is probability of test being negative given one does not have the disease.

Roche tested 5,272 blood samples and found to have specificity greater than was 99.81% and a sensitivity of 100%.

Another study<sup>9</sup> in the UK tested the effectiveness of saliva specimens. 132 patients underwent combined OP/NP swab and saliva collection during the same clinic visit. The sensitivity was 83.3%, while the specificity was 99.1%. The study also calculated the positive predictive value (PPV) which is the probability of having the disease if an individual tests positive, resulting in 93.8%. Lastly, the negative predictive value (NPV), which is the probability of not having the disease if an individual tests negative was 97.4%.<sup>9</sup>

### Comparison to the SARS Outbreak in 2002

#### 1 November 2002 to 31 July 2003<sup>11</sup>

Areas	Total Cases	Total Deaths
Australia	6	0
Brazil	1	0
Canada	251	41
China	5327	349
China, Hong Kong Special Administrative Region	1755	300
China, Macao Special Adnmisitrative Region	1	0
China, Taiwan	665	180
Colombia	1	0
Finland	1	0
France	7	1
Germany	9	0
India	3	0
Indonesia	2	0
Italy	4	0
Kuwait	1	0
Malaysia	5	2
Mongolia	9	0
New Zealand	1	0
Philippines	14	2
Republic of Ireland	1	0
Republic of Korea	3	0
Romania	1	0
Russian Federation	1	0
Singapore	238	33
South Africa	1	1
Spain	1	0
Sweden	3	0
Switzerland	1	0
Thailand	9	2
United Kingdom	4	0
United States	33	0
Viet Nam	63	5
Total	8422	916

Both viruses – SARS-CoV-2 and SARS – originated in China and are spread through respiratory droplets. Both had a more severe effect for older individuals of ages greater than 60.

The CDC reported ~8,098 people were infected with SARS in 26 countries and a total of 774 individuals died.<sup>3</sup> This number is significantly smaller than the number of infected cases from the coronavirus.

There has been research suggesting that both originated and came from bats, specifically horseshoe bats. In 2002, horseshoe bats were sold in China's wet markets. The SARS outbreak occurred in Guangdong province and has been linked to these specific wet markets.<sup>3</sup> By 2019, these bats were no longer sold in the markets.

However, these bats don't live near Wuhan, therefore there isn't a clear reason for the origin of the SARS-CoV-2. According to Wuhan University, COVID-19 was linked to horseshoe bats, but are currently used in research and two labs in Wuhan are studying this. Research suggest that the scientist may have been bitten by a bat and became infected, starting the spread<sup>3</sup> but there is no clear consensus.

#### Appendix

#### **Data and Tables**

Caution taken when looking at data as it might not be fully accurate. Various sources have slight differences in the total counts.

#### Work Cited

<sup>1</sup>Coronavirus Disease 2019 (CDC). (2020). Retrieved 22 July 2020, from https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html

<sup>2</sup>Coronavirus Infections Much Higher Than Reported Cases in Parts of U.S., Study Shows. (NY Times 2020). Retrieved 22 July 2020, from https://www.nytimes.com/2020/07/21/health/coronavirus-infections-us.html

<sup>3</sup>Dutton, G. (2020, April 03). Compare: 2003 SARS Pandemic Versus 2020 COVID-19 Pandemic. Retrieved June 24, 2020, from https://www.biospace.com/article/comparison-2003-sars-pandemic-vs-2020-covid-19-pandemic/

<sup>4</sup>Folegatti, P., Ewer, K., Aley, P., Angus, B., Becker, S., & Belij-Rammerstorfer, S. et al. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. doi: 10.1016/s0140-6736(20)31604-4

<sup>5</sup>Key Role of Specificity in COVID-19 Antibody Test Accuracy. (2020). Retrieved 22 July 2020, from https://diagnostics.roche.com/us/en/roche-blog/key-role-of-specificity-in-covid-19-antibody-test-accuracy.html

<sup>6</sup>Kupferschmidt, K. (2020, June 09). Three big studies dim hopes that hydroxychloroquine can treat or prevent COVID-19. Retrieved June 23, 2020, from https://www.sciencemag.org/news/2020/06/three-big-studies-dim-hopes-hydroxychloroquine-can-treat-or-prevent-covid-19

<sup>7</sup>Naming the coronavirus disease (COVID-19) and the virus that causes it. (2020, February 11). Retrieved from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it#:~:text=ICTV on 11 February 2020.

<sup>8</sup>Pradhan, R. (2020). As Problems Grow With Abbott's Fast COVID Test, FDA Standards Are Under Fire. Retrieved 22 July 2020, from https://khn.org/news/abbott-rapid-test-problems-grow-fda-standards-on-covid-tests-under-fire/

<sup>9</sup>Skolimowska K, Rayment M, Jones R, Madona P, Moore LS, Randell P. Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence [published online ahead of print, 2020 Jul 17]. Clin Microbiol Infect. 2020;S1198-743X(20)30421-3. doi:10.1016/j.cmi.2020.07.015

<sup>10</sup>Tran, J. (2020, June 18). COVID-19 Treatments: An Updated List of Drugs and Medications in Development - GoodRx. Retrieved June 23, 2020, from https://www.goodrx.com/blog/coronavirus-treatments-on-the-way/

 $^{11}\mathrm{WHO}.~(2020).$  Coronavirus disease (COVID-2019) situation reports. WHO. Retrieved June 22, 2020, from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.